Cox proportional hazard model analysis of survival in end-stage renal disease patients with small-sized high-density lipoprotein particles

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 635-641

  Vekic, Jelena ^a   Zeljkovic, Aleksandra ^a   Bogavac Stanojevic, Natasa ^a   Jelic Ivanovic, Zorana ^a   Spasojevic Kalimanovska, Vesna ^a   Simic Ogrizovic, Sanja ^b   Dopsaj, Violeta ^a   Spasic, Slavica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

C reactive protein; Haemodialysis; HDL size; Inflammation; Renal disease

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GEL ELECTROPHORESIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

C-REACTIVE PROTEIN; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS;

EID: 79955794222     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.02.002     Document Type: Article

References (40)

1. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
2. Weiner D.E., Tighiouart H., Elsayed E.F., et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007, 50:217-224.
3. Prichard S.S. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003, 14:S315-S320.
4. Tsompanidi E.M., Brinkmeier M.S., Fotiadou E.H., Giakoumi S.M., Kypreos K.E. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2010, 208:3-9.
5. Rizzo M., Berneis K., Zeljkovic A., Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses?. Clin Lab 2009, 55:421-429.
6. Iseki K., Tozawa M., Yoshi S., Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999, 14:1956-1960.
7. Simic-Ogrizovic S., Dopsaj V., Bogavac-Stanojevic N., Obradovic I., Stosovic M., Radovic M. Serum amyloid-A rather than C-reactive protein is a better predictor of mortality in hemodialysis patients. Tohoku J Exp Med 2009, 219:121-127.
8. Garred L.J., Barichello D.L., DiGiuseppe B., McCready W.G., Canaud B.C. Simple Kt/V formulas based on urea mass balance theory. ASAIO J 1994, 40:997-1004.
9. Rainwater D.L., Moore P.H., Gamboa I.O. Improved method for making nondenaturing composite gradient gels for the electrophoretic separation of lipoproteins. J Lipid Res 2004, 45:773-775.
10. Vekic J., Topic A., Zeljkovic A., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem 2007, 40:310-316.
11. Zeljkovic A., Spasojevic-Kalimanovska V., Vekic J., et al. Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk?. Clin Exp Med 2008, 8:109-116.
12. Vekic J., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V., et al. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis 2009, 203:236-242.
13. Herzog C.A., Ma J.Z., Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339:799-805.
14. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003, 41:11-17.
15. Fleischmann E.H., Bower J.D., Salahudeen A.K. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J 2001, 47:74-81.
16. Iseki K., Yamazato M., Tozawa M., Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002, 61:1887-1893.
17. Kilpatrick R.D., McAllister C.J., Kovesdy C.P., Derose S.F., Kopple J.D., Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007, 18:293-303.
18. Pecoits-Filho R., Lindholm B., Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002, 17:28-31.
19. Zeljkovic A., Vekic J., Spasojevic-Kalimanovska V., et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010, 210:548-554.
20. Kimura H., Miyazaki R., Imura T., et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int 2003, 64:1829-1837.
21. Mekki K., Prost J., Remaoun M., Belleville J., Bouchenak M. Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients. BMC Cardiovasc Disord 2009, 9:41.
22. Vaziri N.D., Liang K., Parks J.S. Downregulation of lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int 2001, 59:2192-2196.
23. Tall A.R., Krumholz S., Olivecrona T., Deckelbaum R.J. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 1985, 26:842-851.
24. Attia N., Nakbi A., Smaoui M., et al. Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease. Tohoku J Exp Med 2007, 213:129-137.
25. Attia N., Domingo N., Lorec A.M., et al. Reverse modulation of the HDL anionic peptide factor and phospholipid transfer protein activity in coronary artery disease and type 2 diabetes mellitus. Clin Biochem 2009, 42:845-851.
26. Schlitt A., Heine G.H., Jiang X.C., et al. Phospholipid transfer protein in hemodialysis patients. Am J Nephrol 2007, 27:138-143.
27. Moorhead J.F., Wheeler D.C., Varghese Z. Glomerular structures and lipids in progressive renal disease. Am J Med 1989, 87:N12-N20.
28. Magil A.B. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol 1999, 12:33-40.
29. Moradi H., Yuan J., Ni Z., Norris K., Vaziri N.D. Reverse cholesterol transport pathway in experimental chronic renal failure. Am J Nephrol 2009, 30:147-154.
30. Moradi H., Pahl M.V., Elahimehr R., Vaziri N.D. Impaired antioxidant activity of HDL in chronic kidney disease. Transl Res 2009, 153:77-85.
31. Fournier N., Paul J.L., Atger V., et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 1997, 17:2685-2691.
32. Oram J.F., Vaughan A.M. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006, 99:1031-1043.
33. Bergt C., Pennathur S., Fu X., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 2004, 101:13032-13037.
34. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
35. Memon L., Spasojevic-Kalimanovska V., Bogavac-Stanojevic N., et al. Association of C-reactive protein with the presence and extent of angiographically verified coronary artery disease. Tohoku J Exp Med 2006, 209:197-206.
36. Honda H., Qureshi A.R., Heimbürger O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006, 47:139-148.
37. Navab M., Reddy S., Van Lenten B.J., Anantharamaiah G.M., Fogelman A.M. Role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009, 50:S145-S149.
38. Bang C.A., Bro S., Bartels E.D., Pedersen T.X., Nielsen L.B. Effect of uremia on HDL composition, vascular inflammation, and atherosclerosis in wild-type mice. Am J Physiol Renal Physiol 2007, 293:F1325-F1331.
39. Alabakovska S.B., Todorova B.B., Labudovic D.D., Tosheska K.N. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem 2002, 35:211-216.
40. Yeo Y., Byun S.W., Lee J.Y., Min W.K., Park J.S., Kim S.B. Lack of association between small dense low-density lipoprotein levels and coronary artery disease in chronic hemodialysis patients. Am J Nephrol 2009, 30:310-314.